Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiolabelled TA-8995 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TA-8995 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUC of TA-8995 | 35 days | |
| Mass balance recovery of total radioactivity from excreta for radiolabelled TA-8995 | 35 days | |
| Measure the amount of radiolabelled TA-8995 recovered from urine and faeces. | 35 days | |
| Measure the levels of major metabolites of TA-8995 in plasma, urine and faeces after oral administration of radiolabelled TA-8995 | 35 days | |
| Elimination of half-life of radiolabelled TA-8995 | 35 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse events | 35 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ashley Brooks | Covance | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Covance Clinical Research Unit Ltd | Leeds | LS2 9LH | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000597751 | TA-8995 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided